3D QSAR models for α2a-adrenoceptor agonists

Neurochemistry International

Volumn 51, Issue 5, 2007, Pages 268-276

  Balogh, Balázs ^a,b   Jójárt, Balázs ^c   Wágner, Zsolt ^a,b   Kovács, Péter ^a   Máté, Gáspár ^a   Gyires, Klára ^a   Zádori, Zoltán ^a   Falkay, György ^c   Márki, Árpád ^c   Viskolcz, Béla ^c   Mátyus, Péter ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Szentagothai Knowledge Center   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

2a Adrenergic receptor agonist; 3D QSAR (3 dimensional quantitative structure activity relationship); CoMFA (comparative molecular field analysis); DISCOtech (distance comparison); Region focusing

Indexed keywords

2 (2,6 DIETHYLANILINO) 2 IMIDAZOLINE; 5,6 DIHYDROXY 1 (2 IMIDAZOLIN 2 YL)TETRALIN; 6 (2 CHLORO 6 FLUOROPHENYL) 2,3,6,7 TETRAHYDRO 5H PYRROLO[1,2 A]IMIDAZOLE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; APRACLONIDINE; BRIMONIDINE; CLONIDINE; CORBADRINE; DEXMEDETOMIDINE; GUANABENZ; GUANFACINE; LEVLOFEXIDINE; NAPHAZOLINE; NORADRENALIN; OXYMETAZOLINE; TALIPEXOLE; TRAMAZOLINE; UNCLASSIFIED DRUG; XYLAZINE; XYLOMETAZOLINE;

ARTICLE; CALCULATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY; TECHNIQUE; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS;

ADRENERGIC ALPHA-AGONISTS; ALGORITHMS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ADRENERGIC, ALPHA-2; REPRODUCIBILITY OF RESULTS;

EID: 34548524492     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.05.021     Document Type: Article

References (44)

1. 2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56 (1999) 154-161
2. 2-adrenoceptors upon MPTP-induced behaviour deficits in mice. J. Neural Transm. 110 (2003) 183-200
3. Ashman, W.P., Mickiewicz, A.P., Nelson, T.M., 1992. Computer-Assisted Determination of Minimum Energy Conformations. VI: A Pharmacophore Model of the Active Region of the alpha2-Adrenoceptor. Report (1992), (CROEC-TR-398; Order No. AD-A262-108), 42 pp. CAN 120:208743 AN 1994:208743 CAPLUS.
4. Balogh B., Hetényi C., Keseru{combining double acute accent} M.G., and Mátyus P. Structure-based calculation of binding affinities of alpha2A-adrenoceptor agonists. Chem. Med. Chem. 2 (2007) 801-805
5. Blake D.W., Ludbrook J., and Van Leeuwen A.F. Dexmedetomidine and hemodynamic responses to acute central hypovolemia in conscious rabbits. Clin. Exp. Parmacol. Physiol. 27 (2000) 801-809
6. 1A receptor ligands. Chemomet. Intel. Lab. Syst. 47 (1999) 239-252
7. Carrieri A., Brasili L., Leonetti F., Pigini M., Giannella M., Bousquet P., and Carotti A. 2-D and 3-D modeling of imidazoline receptor ligands: insights into pharmacophore. Bioorg. Med. Chem. 5 (1997) 843-856
8. 2-guided region selection for comparative molecular field analysis (CoMFA): a simple method to achieve consistent results. J. Med. Chem. 38 (1995) 1060-1066
9. Clark M., Cramer III R.D., and van Opdenhosch N. Validation of the general purpose Tripose 5.2 force field. J. Comp. Chem. 10 (1989) 982-1012
10. Cramer R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA). 1: Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
11. De Benedetti P.G., Fanelli F., Menziani M.C., and Cocchi M. The ad hoc supermolecule approach to receptor ligand design. J. Mol. Struct.: THEOCHEM 503 (2000) 1-16
12. 2-adrenoceptors. Eur. J. Pharmacol. 361 (1998) 1-15
13. Elenkov I.J., Wilder R.L., Chrousos G.P., and Vizi E.S. The synpatic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52 (2000) 595-638
14. Fenton C., Keating G.M., and Lyseng-Williamson K.A. Moxonidine: a review of its use in essential hypertension. Drugs 66 (2006) 477-496
15. Francois G., and Gary A.J. Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors. Neuropsychopharmacology 28 (2003) 1140-1149
16. 2-adrenoceptor subtypes involved in gastric emptying, gastric motility and gastric mucosal defense. Eur. J. Pharmacol. 528 (2005) 150-157
17. Gasteiger J., and Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36 (1980) 3219-3228
18. Georges F., Caillé S., Vouillac C., Le Moine C., and Stinus L. Role of imidazoline receptors in the anti-aversive properties of clonidine during opiate withdrawal in rats. Eur. J. Neurosci. 22 (2005) 1812-1816
19. 2 receptor affinity. J. Med. Chem. 48 (2005) 6620-6631
20. 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn-Schmiedeberg Arch. Pharmacol. 368 (2003) 342-351
21. Hein L., Altman J.D., and Kobilka B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 (1999) 181-183
22. 2-adrenoceptor agonists with gastroprotective effects. Life Sci. 70 (2002) 2857-2869
23. 2 adrenergic receptors. Biochem. Pharmacol. 55 (1998) 1035-1043
24. Kapoor K., Willems E.W., MaassenVanDenBrink A., Hiligers J.P.C., Cordi A.A., and Vayssettes-Courchay C. Assessment of anti-migraine potential of a novel α-adrenoceptor agonist S19014: effects on porcine carotid and regional haemodynamics and human coronary artery. Cephalalgia 24 (2004) 425-438
25. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65 (2004) 2-11
26. Klebe G., and Ute A. On the prediction of binding properties of drug molecules by comparative molecular field analysis. J. Med. Chem. 36 (1993) 70-80
27. Kobinger W., and Pichler L. Alpha 2-adrenoceptor agonistic effect of B-HT 920 in isolated perfused hindquarters of rats. Eur. J. Pharmacol. 76 (1981) 101-105
28. Kubinyi H., Hamprecht F.A., and Mietzner T. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J. Med. Chem. 41 (1998) 2553-2564
29. Li Y., Wang Y., Yang L., Zhang S., and Liu C. Structural determinants of flavones interacting with the C-terminal nucleotide-binding domain as P-glycoprotein inhibitors. IEJMD 5 (2006) 1-12
30. 2-Adrenergic Receptor Subtypes b and c. Science 273 (1996) 803-805
31. Lê A.D., Harding S., Juzytsch W., Funk D., and Shaham Y. Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology 179 (2005) 366-373
32. 2a-adrenergic receptor subtype. Science 273 (1996) 801-803
33. Martin Y.C., Bures M., and Danaher E. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonist. J. Comput. Aided Mol. Des. 7 (1993) 83-102
34. 2-adrenoceptor agonists and b-endorphin in rats. Eur. J. Pharmacol. 435 (2002) 225-229
35. Novellino E., Fattorusso C., and Greco G. Use of comparative molecular field analysis and cluster analysis in series design. Pharm. Acta Helv. 70 (1995) 149-154
36. Philipp M., and Hein L. Adrenergic knockout mice: distinct functions of 9 receptor subtypes. Pharm. Ther. 101 (2004) 65-74
37. Remko M., Owen A.W., and Richards W.G. Molecular structure and gas-phase reactivity of clonidine and rilmenidine: two-layered ONIOM calculations. Phys. Chem. Chem. Phys. 3 (2001) 901-907
38. Romero-Sandoval A., and Eisenach J.C. Perineural clonidine reduces mechanical hypersensitivity and cytokine production in established nerve injury. Anesthesiology 104 (2006) 351-355
39. Savolainen J., Rautio J., Razetti R., and Jaevinen T. A novel D2-dopaminergic and α2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits. J. Pharm. Pharmacol. 55 (2003) 789-794
40. 2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 68 (2001) 2277-2285
41. Schweimer J., Fendt M., and Schnitzler H.U. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats. Eur. J. Pharmacol. 507 (2005) 117-124
42. Tham S.M., Angus J.A., Tudor E.M., and Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ-opioid receptor and α2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 144 (2005) 875-884
43. 2-adrenoceptor agonist rilmenidine. Am. J. Cardiol. 61 (1988) 6D-14D
44. Wermuth C.G. The Practice of Medicinal Chemistry (1996), Academic Press Limited